Respiratory Syncytial Virus Vaccine – March 2026

Powder and suspension for injection (0.5 mL)

  • Brand names:
    • Arexvy®
  • Pharmaceutical Company:
    • GLAXOSMITHKLINE AUSTRALIA PTY LT
  • Condition/Indication: Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026